Avanos Medical (NYSE:AVNS - Get Free Report) updated its fourth quarter 2024 earnings guidance on Monday. The company provided EPS guidance of 0.380-0.430 for the period, compared to the consensus EPS estimate of 0.400. The company issued revenue guidance of $175.0 million-$180.0 million, compared to the consensus revenue estimate of $177.2 million. Avanos Medical also updated its Q4 guidance to $0.38-0.43 EPS.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded Avanos Medical from a "strong-buy" rating to a "buy" rating in a report on Sunday, November 3rd.
Check Out Our Latest Report on AVNS
Avanos Medical Stock Up 4.2 %
Shares of AVNS stock traded up $0.64 on Monday, reaching $15.84. 745,714 shares of the company were exchanged, compared to its average volume of 862,623. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. Avanos Medical has a one year low of $14.98 and a one year high of $25.36. The company has a 50-day moving average of $17.84 and a 200-day moving average of $20.93. The company has a market cap of $727.96 million, a price-to-earnings ratio of 46.59 and a beta of 0.99.
About Avanos Medical
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
